Extrait

This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.

Critère d'inclusion

• Atrial fibrillation ,Thromboembolism

Pays

• Belarus
• Belgium
• Bosnia and Herzegovina
• Canada
• Chile
• Latvia
• Mexico
• Moldova, Republic of
• Russian Federation
• Slovakia
• Ukraine
• United States

Liens

• ictrp
• nct